Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110

Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires. On June 10, Mizuho analyst Graig Suvannavejh reaffirmed his Outperform rating on Insmed and raised the price target from $96 to $110.

The revision follows the encouraging Phase 2b results for Treprostinil Palmitil Inhalation Powder (TPIP) in treating pulmonary arterial hypertension. Suvannavejh describes the data as highly positive, suggesting TPIP could become a leading treatment option in the respective area.

Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110

A scientist using sophisticated laboratory equipment to analyze a sample of a therapeutic candidate.

The analyst believes the trial’s success strengthens Insmed’s growth outlook and opens the door for further upside to current earnings estimates. The tone of the note reflects the analyst’s strong confidence in TPIP’s potential and its impact on Insmed’s long-term value.

Insmed Inc. (NASDAQ:INSM) is a global biopharmaceutical company that develops therapies for serious diseases. It has a commercial product, ARIKAYCE, and a pipeline that includes clinical-stage programs, brensocatib, TPIP, and INS1201, as well as pre-clinical research programs.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.